Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation.

Maria Stelmachowska-BanaśIzabella Czajka-OraniecAgnieszka TomasikWojciech Zgliczyński

Published in: Pituitary (2021)

This real-life study confirmed good effectiveness of pasireotide-LAR in patients resistant to first-generation SRLs. Pasireotide-LAR was overall safe and well tolerated, however significant glucose metabolism worsening was noted.

Keyphrases

end stage renal disease
ejection fraction
randomized controlled trial
newly diagnosed
chronic kidney disease
systematic review
prognostic factors
peritoneal dialysis
growth hormone